New data seem to indicate that more children are suffering from the vaccine meant to protect them from COVID-19 than from the virus itself.

“three of the 1,228 reported cases of adverse effect have resulted in the death of the patients within two to twenty-four days following vaccination with [Pfizer/BioNTech].”

New data seems to indicate that more children are suffering from the vaccine meant to protect them from COVID-19 than from the virus itself.

https://www.lifesitenews.com/news/vaccines-for-kids-potentially-more-dangerous-than-covid-german-govt-report-indicates/

+
27.3% of those vaccinated had not yet recovered at the time of reporting

https://www.pei.de/SharedDocs/Downloads/DE/newsroom/dossiers/sicherheitsberichte/sicherheitsbericht-27-12-bis-31-08-21.pdf?__blob=publicationFile&v=5

57.6% of those vaccinated were fully recovered or on the mend at the time of reporting,

27.3% had not yet recovered at the time of reporting, and

the outcome was unknown in 16% of the children and adolescents.

Three of the 1,228 reports of suspected cases relate to a fatal outcome between two and 24 days after vaccination with Comirnaty.

All three cases concern male children and adolescents.

+++

Excerpts Below:

Suspected cases of side effects and vaccination complications after vaccination to protect against COVID-19 since the start of the vaccination campaign on December 27, 2020 to August 31, 2021

The Paul Ehrlich Institute (PEI) reports over 156,360 suspected cases of side effects or vaccination complications related to time in Germany vaccination with

the mRNA vaccines

Comirnaty (BioNTech Manufacturing GmbH),

Spikevax (MODERNA BIOTECH SPAIN, SL) and

the vector vaccines

Vaxzevria (AstraZeneca AB) and

COVID-19 Vaccine Janssen

to protect against COVID-19 from the start of the vaccination campaign on December 27, 2020 until August 31, 2021.

According to the Robert Koch Institute, 101,877,124 vaccinations were carried out by August 31, 2021, of which 76,982,568 vaccinations with Comirnaty, 9,396,381 vaccinations with Spikevax, 12,645,915 vaccinations with Vaxzevria and 2,852,260 vaccinations with COVID-19 Vaccine Janssen.

84,763 suspected cases of vaccination with Comirnaty were reported,

24,457 suspected cases of Spikevax,

41,534 suspected cases of Vaxzevria and

4,895 reports of COVID-19 Vaccine Janssen.

In 711 reported suspected cases, the COVID-19 vaccine was not specified.

The reporting rate for all vaccines together was 1.5 reports per 1,000 vaccine doses, for serious reactions 0.15 reports per 1,000 vaccine doses.

+++

5. Children and young people between 12 and 17 years since May 31, 2021

Comirnaty is also approved for the vaccination of 12 to 15 year olds and since July 23, 2021 Spikevax has been approved for the 12 to 17 year old age group. Both vaccines are therefore approved from the age of 12 years. On August 16, 2021, the Standing Vaccination Commission (STIKO) issued the COVID-19 vaccination recommendation for all children and adolescents from the age of twelve and thus expanded the initial vaccination recommendation.

Since the start of the vaccination campaign on December 27, 2020, a total of 1,228 suspected side effects have been reported to the Paul Ehrlich Institute in which at least one vaccination reaction was reported in children and adolescents after vaccination with COVID-19 vaccines.

Page 15/36

Although only the two mRNA vaccines are currently approved for children and adolescents from the age of twelve, 25 suspected cases of vector-based vaccines were also reported to the Paul Ehrlich Institute.

A total of 14.1% of the reports described serious adverse reactions. In relation to the extrapolated vaccination doses (see methodology), this is 0.67 suspected cases per 1,000 vaccination doses Comirnaty.

Injection site pain, headache, fatigue, and fever were most commonly reported (Figure 5).

+++

57.6% of those vaccinated were fully recovered or on the mend at the time of reporting, 27.3% had not yet recovered at the time of reporting, and the outcome was unknown in 16% of the children and adolescents.

Three of the 1,228 reports of suspected cases relate to a fatal outcome between two and 24 days after vaccination with Comirnaty.

All three cases concern male children and adolescents.

Injection site pain

headache

fatigue

fever

Dizziness

chills

Flu-like illness

nausea

Rash

malaise

Menstrual disease

Lymphadenopathy

Limb discomfort

Myalgia

Myocarditis

Vomit

Feeling of warmth

Dyspnoea

Swelling at the injection site

cough

Paraesthesia

Tachycardia

Injection site erythema

Reaction at the vaccination site

syncope

Chest pain

Pain in a limb

% of all reported vaccination reactions in children and adolescents after COVID-19 vaccination

Page 17/36

two of the deceased suffered from serious previous illnesses.

Multiple organ failure, pulmonary hemorrhage, disseminated intravascular coagulation, septic shock and fever in one case, fever and circulatory collapse in the second case and pulmonary embolism in the third were reported.

In all three cases, the causal connection with the vaccination cannot yet be assessed.

In all three cases, however, the symptoms and the course are different. There were no clinical similarities.

The percentage of adverse reactions of particular interest after both mRNA vaccines that were reported more than once relative to the total number of reported reactions is shown in Figure 6.

Similar to adults, there are reports of myo- / pericarditis.

As of August 31, 2021, the Paul Ehrlich Institute had received 58 reports of myo- / pericarditis in children and adolescents aged 12 to 17 years.

53 boys and four girls (n = 54 cases of myocarditis, n = 3 cases of isolated pericarditis) were affected.

The sex of a 13-year-old child with myocarditis after the second Comirnaty vaccination was not given.

In male children and adolescents, the reactions occurred in 36 cases after the second vaccination and in 14 cases after the first vaccination.

No information on the vaccination dose was given in three reports.

In female children and adolescents, the reactions occurred twice after the first dose and twice after the second dose.

The reporting rate of myo- / pericarditis in male children and adolescents was 1 case for 17,271 vaccination doses and for female children and adolescents 1 case for 212,766 vaccination doses.

A comparison of the reported cases of myocarditis with the statistically randomly expected cases

(Background rate determined on the basis of data from insured persons from Germany from 2020)

within a time interval of 21 days resulted in an expected number of myocarditis of 5.6 to 7.6 cases for boys (analysis 1)

based on the calculated vaccination rate (analysis 2) taking into account the under-recording of the vaccination rate).

51 cases were reported.

In female children and adolescents with myocarditis, the expected number matched the reported value (n = 3).

+++

The outcome of the adverse reactions to myo- / pericarditis according to Comirnaty at the time of reporting is shown in Figure 7.

Figure 7: Outcome of myo- / pericarditis reactions

Myo- / pericarditis

Seizure

arrhythmia

Facial paralysis

Thrombocytopenia / ITP

Herpes zoster

Anaphylactic shock

Anaphylactic reaction

Encephalitis

Multisystem Inflammatory Syndrome

Multiorgandysfunction Syndrome

Pulmonary embolism

Deep vein thrombosis

Cerebral infarction

restored

not yet restored

Improvement unknown

Page 19/36

In one adolescent, a pediatric inflammatory multisystem syndrome (PIMS, multisystem inflammatory syndrome, also called multisystem inflammatory syndrome in children, multisystem inflammatory syndrome in children, MIS-C) was identified about four weeks after the Comirnaty vaccination reported.

The case corresponds to level 1 of the case definition of the Brighton Collaboration.

Extensive diagnostic examinations have largely ruled out other causes, including an asymptomatic past or coincident COVID-19 infection, so that a connection with the vaccination is likely.

The young person has now recovered.

Two other cases also describe reactions that could indicate PIMS (MIS-C).

Both reports cannot be conclusively assessed at the moment, as further information is still pending.

The European Medicines Agency (EMA) has announced an extensive analysis of the reports by the Pharmacovigilance Risk Assessment Committee (PRAC).

Multisystem inflammatory syndrome is a serious inflammatory disease that affects many parts of the body and can cause symptoms such as fatigue, persistent high fever, diarrhea, vomiting, abdominal pain, headache, chest pain, and difficulty breathing.

The syndrome has been reported very rarely as a result of COVID-19 illness.

+++